Monday, October 17, 2016

MEDIJEL GEL





1. Name Of The Medicinal Product



MEDIJEL GEL


2. Qualitative And Quantitative Composition







Lidocaine Hydrochloride BP

0.66% w/w

Aminoacridine Hydrochloride BP 1968

0.05% w/w


3. Pharmaceutical Form



Oral Gel



4. Clinical Particulars



4.1 Therapeutic Indications



The quick, effective relief from the pain of common mouth ulcers, soreness of gums and denture rubbing. Medijel Gel is administered directly onto the affected area with a clean finger or small pad of cotton wool.



4.2 Posology And Method Of Administration



The gel should be applied directly to the affected area(s) with a clean finger or small pad of cotton wool. If necessary application may be repeated after 20 minutes.



Each dose is approximately 300mg, i.e. 2mg of Lidocaine Hydrochloride and 0.15mg of Aminoacridine Hydrochloride. Medijel Gel can be used as directed for adults and children.



4.3 Contraindications



Hypersensitivity to the active substances or to any other of the ingredients.



Contains sucrose. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.



4.4 Special Warnings And Precautions For Use



If symptoms persist longer than 7 days following the use of the product a doctor or dentist should be consulted.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



None stated.



4.6 Pregnancy And Lactation



The safety of Medijel Gel during pregnancy and lactation has not been established, but is considered not to constitute a hazard.



4.7 Effects On Ability To Drive And Use Machines



None stated.



4.8 Undesirable Effects



Hypersensitivity reactions to Lidocaine have been reported on rare occasions.



4.9 Overdose



Maximum safe dosage for a 70kg adult is 750mg for Lidocaine (Goodman & Gilman, page 313). A tube of Medijel Gel contains 82.5mg of Lidocaine hydrochloride - overdose is not a problem.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



Lidocaine Hydrochloride is well documented in Martindale 28th Edition Page 900-904 and Goodman & Gilman, Chapter 15 and pages 767-770.



Lidocaine Hydrochloride was first introduced in 1948 and is one of the most widely used local anaesthetics, producing more prompt, more intense, longer lasting and more extensive anaesthesia than does an equal concentration of procaine (Peak anaesthesia within 2-5 minutes). Local anaesthetics are drugs that block nerve conduction when applied locally to nerve tissue in appropriate concentrations. They have good powers of penetration and their action is reversible. Their use is followed by complete recovery in nerve function with no evidence of structural damage to nerve fibres or cells.



Aminoacridine Hydrochloride is a slow acting disinfectant. It exerts germicidal action against bacteria and fungi. It is also used as a surgical and endodontic irrigant and to treat local infections of the ear, mouth and throat. Its exact mode of action is not known but it involves disruption of certain metabolic pathways.



5.2 Pharmacokinetic Properties



Lidocaine is readily absorbed through mucous membranes. They exert their effects in the form of the non-ionised base. Lidocaine undergoes first-pass metabolism in the liver and bioavailability is low after administration by mouth. It is rapidly de-ethylated to the active metabolite monoethylglycinexylidide and then hydrolysed by amidases to various compounds, including glycineexylidide which has reduced activity but a longer elimination half-life. Less than 10% of a dose is excreted unchanged via the kidneys. The metabolic products are excreted in the urine.



Aminoacridine Hydrochloride if administered systematically is rapidly eliminated through the kidney (0.2 grams being eliminated from the blood in 30 minutes). (Medijel Gel dose 0.15mg Aminoacridine hydrochloride).



5.3 Preclinical Safety Data



There are no pre-clinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC.



6. Pharmaceutical Particulars



6.1 List Of Excipients



Glycerol , Hydroxypolyethoxydodecane HSE, Alcohol 96% v/v, Carbomer, Sucrose, Saccharin Sodium, Peppermint Oil, Ethyl vanillin, Di-isopropanolamine 90% aqueous, Purified Water



6.2 Incompatibilities



None encountered.



6.3 Shelf Life



36 months.



6.4 Special Precautions For Storage



Do not store above 25°C.



6.5 Nature And Contents Of Container



Aluminium tube with membrane seal and spiked polyethylene cap.



6.6 Special Precautions For Disposal And Other Handling



N/A



7. Marketing Authorisation Holder



DDD LIMITED



94, Rickmansworth Road, Watford, Hertfordshire, United Kingdom, WDI8 7JJ.



8. Marketing Authorisation Number(S)



PL 0133/5000R



Legal Status: GSL



9. Date Of First Authorisation/Renewal Of The Authorisation



Date of last renewal: 20/05/03



10. Date Of Revision Of The Text



March 2010




No comments:

Post a Comment